Literature DB >> 8788069

Effects on locomotor activity after local application of D3 preferring compounds in discrete areas of the rat brain.

T Kling-Petersen1, E Ljung, K Svensson.   

Abstract

Compounds showing an in vitro binding preference for the dopamine D3 vs. D2 receptors were tested for effects on locomotor activity after local application in the nucleus accumbens (N Acc) and the ventral tegmental area (VTA) of the rat brain. R-(+)-7-OH-DPAT, a dopamine D3 preferring agonist, inhibited spontaneous locomotor activity over a wide dose range after injection into the N Acc. A decrease in activity over a wide dose range was also seen after local application into the VTA of both R-(+)-7-OH-DPAT and the dopamine D2 preferring agonist (+)-3-PPP. Furthermore, (+)-3-PPP produced a dose dependent increase in activity after local application into the N Acc. The putative D3 antagonist, U99194A, with a 30 fold preference for the dopamine D3 vs. D2 receptor, produced an increase in activity when injected into the N Acc. A similar pattern were seen after infusion into the lateral ventricle. Local application into the VTA did, however, not produce any significant effects. The present results support the hypothesis that dopamine D3 receptors (in contrast to the D2 receptors) are mainly postsynaptically located where they display an inhibitory action on locomotor activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8788069     DOI: 10.1007/bf01281155

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  22 in total

1.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.

Authors:  P Sokoloff; B Giros; M P Martres; M L Bouthenet; J C Schwartz
Journal:  Nature       Date:  1990-09-13       Impact factor: 49.962

2.  Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other "D-2-like" agonists.

Authors:  S A Daly; J L Waddington
Journal:  Neuropharmacology       Date:  1993-05       Impact factor: 5.250

3.  Suppression of exploratory locomotor activity in the rat by the local application of 3-PPP enantiomers into the nucleus accumbens.

Authors:  L Svensson; S Ahlenius
Journal:  Eur J Pharmacol       Date:  1983-04-08       Impact factor: 4.432

4.  Modulation of cocaine self-administration in the rat through D-3 dopamine receptors.

Authors:  S B Caine; G F Koob
Journal:  Science       Date:  1993-06-18       Impact factor: 47.728

5.  Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP.

Authors:  S Hjorth; A Carlsson; D Clark; K Svensson; H Wikström; D Sanchez; P Lindberg; U Hacksell; L E Arvidsson; A Johansson
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

6.  Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release.

Authors:  K Svensson; A Carlsson; N Waters
Journal:  J Neural Transm Gen Sect       Date:  1994

7.  Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors.

Authors:  K Svensson; A Carlsson; R M Huff; T Kling-Petersen; N Waters
Journal:  Eur J Pharmacol       Date:  1994-10-03       Impact factor: 4.432

8.  Desenkephalin-gamma-endorphin and neuroleptics counteract the DP-7-ATN-induced hypomotility after intra-accumbens treatment.

Authors:  F S Radhakishun; A S Horn; J M Van Ree
Journal:  Eur J Pharmacol       Date:  1988-02-16       Impact factor: 4.432

9.  Sensitization and individual differences to IP amphetamine, cocaine, or caffeine following repeated intracranial amphetamine infusions.

Authors:  M S Hooks; G H Jones; B J Liem; J B Justice
Journal:  Pharmacol Biochem Behav       Date:  1992-11       Impact factor: 3.533

10.  Effects on locomotor activity after local application of (+)-UH232 in discrete areas of the rat brain.

Authors:  T Kling-Petersen; E Ljung; N Waters; K Svensson
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

View more
  12 in total

1.  C57BL/6J mice exhibit reduced dopamine D3 receptor-mediated locomotor-inhibitory function relative to DBA/2J mice.

Authors:  R K McNamara; B Levant; B Taylor; R Ahlbrand; Y Liu; J R Sullivan; K Stanford; N M Richtand
Journal:  Neuroscience       Date:  2006-08-28       Impact factor: 3.590

2.  Dose-response analysis of locomotor activity and stereotypy in dopamine D3 receptor mutant mice following acute amphetamine.

Authors:  Robert K McNamara; Aaron Logue; Kevin Stanford; Ming Xu; Jianhua Zhang; Neil M Richtand
Journal:  Synapse       Date:  2006-10       Impact factor: 2.562

3.  Chronic Δ⁹-tetrahydrocannabinol exposure induces a sensitization of dopamine D₂/₃ receptors in the mesoaccumbens and nigrostriatal systems.

Authors:  Nathalie Ginovart; Benjamin B Tournier; Marcelle Moulin-Sallanon; Thierry Steimer; Vicente Ibanez; Philippe Millet
Journal:  Neuropsychopharmacology       Date:  2012-06-13       Impact factor: 7.853

4.  D3 dopamine receptor regulation of ETB receptors in renal proximal tubule cells from WKY and SHRs.

Authors:  Changqing Yu; Zhiwei Yang; Hongmei Ren; Yie Zhang; Yu Han; Duofen He; Quansheng Lu; Xiaoyan Wang; Xukai Wang; Chengming Yang; Laureano D Asico; Ulrich Hopfer; Gilbert M Eisner; Pedro A Jose; Chunyu Zeng
Journal:  Am J Hypertens       Date:  2009-04-23       Impact factor: 2.689

5.  Dopamine D3 receptor ligands modulate the acquisition of morphine-conditioned place preference.

Authors:  Henriette Francès; Maria Smirnova; Ludovic Leriche; Pierre Sokoloff
Journal:  Psychopharmacology (Berl)       Date:  2004-04-17       Impact factor: 4.530

6.  Dosage-dependent effect of dopamine D2 receptor activation on motor cortex plasticity in humans.

Authors:  Shane Fresnoza; Elisabeth Stiksrud; Florian Klinker; David Liebetanz; Walter Paulus; Min-Fang Kuo; Michael A Nitsche
Journal:  J Neurosci       Date:  2014-08-06       Impact factor: 6.167

7.  Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15.

Authors:  Béla Kiss; István Laszlovszky; Attila Horváth; Zsolt Némethy; Eva Schmidt; Gyula Bugovics; Károly Fazekas; István Gyertyán; Eva Agai-Csongor; György Domány; Zsolt Szombathelyi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-13       Impact factor: 3.000

8.  Effects on locomotor activity after local application of (+)-UH232 in discrete areas of the rat brain.

Authors:  T Kling-Petersen; E Ljung; N Waters; K Svensson
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

9.  The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats.

Authors:  Mark J Millan; Laetitia Seguin; Alain Gobert; Didier Cussac; Mauricette Brocco
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

10.  Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population.

Authors:  B Almoguera; R Riveiro-Alvarez; J Lopez-Castroman; P Dorado; C Vaquero-Lorenzo; J Fernandez-Piqueras; A Llerena; F Abad-Santos; E Baca-García; R Dal-Ré; C Ayuso
Journal:  Pharmacogenomics J       Date:  2012-01-03       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.